Boothbay Fund Management’s Akero Therapeutics AKRO Stock Holding History

Boothbay Fund Management’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-64,258	Closed	-$3.05M	–	1931
2025 Q3	$3.05M	Buy	64,258 +692	+1%	+$33.5K	0.04%	449
2025 Q2	$3.39M	Sell	63,566 -9,100	-13%	-$414K	0.07%	383
2025 Q1	$2.94M	Buy	+72,666	New	+$3.08M	0.08%	343
2023 Q4	–	Sell	-40,280	Closed	-$2.04M	–	1625
2023 Q3	$2.04M	Buy	+40,280	New	+$1.88M	0.05%	484
2023 Q2	–	Sell	-10,035	Closed	-$384K	–	1763
2023 Q1	$384K	Buy	+10,035	New	+$447K	0.01%	1382
2020 Q1	–	Sell	-10,000	Closed	-$222K	–	831
2019 Q4	$222K	Buy	+10,000	New	+$207K	0.02%	681

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Boothbay Fund Management's AKRO Position: Q4 2025 in Review

Boothbay Fund Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 64,258 shares — an estimated $3.05M sold.

Boothbay Fund Management first reported a position in AKRO in Q4 2019 and held it in 6 quarters. The position peaked at $3.39M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Boothbay Fund Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Boothbay Fund Management sold 64,258 Akero Therapeutics shares in Q4 2025, an estimated $3.05M.
Boothbay Fund Management first reported a position in Akero Therapeutics in Q4 2019 and held it in 6 quarters.
Boothbay Fund Management's Akero Therapeutics position peaked at $3.39M in Q2 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Boothbay Fund Management's 13F filing for Q4 2025, filed 17 Feb 2026.